Ecuador vs Mozambique: Share of the population living with HIV receiving antiretroviral therapy
Ecuador
82.1%
in 2024
Mozambique
81.9%
in 2024
Ecuador rank
45th
Mozambique rank
48th
Share of the population living with HIV receiving antiretroviral therapy over time
- Ecuador
- Mozambique
How they compare
Ecuador currently reports 82.1% against 81.9% in Mozambique, a difference of 0.2%.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Mozambique ahead.
Ecuador ranks 45th and Mozambique ranks 48th of 149 countries.
Ecuador has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Ecuador | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.8% | 0.0% | 0.8% | Ecuador |
| 2000s | 5.5% | 3.3% | 2.2% | Ecuador |
| 2010s | 38.1% | 36.7% | 1.4% | Ecuador |
| 2020s | 76.3% | 71.9% | 4.4% | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Ecuador or Mozambique?
- Ecuador, at 82.1% against 81.9% in Mozambique as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Ecuador and Mozambique?
- 0.2%, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Mozambique?
- 35 years are reported by both, from 1990 to 2024.
- How do Ecuador and Mozambique rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Ecuador ranks 45th and Mozambique ranks 48th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.